• Piri Keşif Aracı

Arama ipuçları nelerdir?
1.  sayfa ve
1
Why is there an emerging need to look for a suitable drug delivery platform in targeting and regulating microbiota?
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
PubMed
Dergi:
Panminerva Med
Yazar(lar) :
Kamal Dua , Gaurav Gupta , Rajendra Awasthi , Dinesh K Chellappan
Yıl :
2018
Dinesh K Chellappan
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
DOI : 10.23736/S0031-0808.18.03446-8
Sınıflandırma :
2
Nanotechnology in drug delivery gaining new perspectives in respiratory diseases.
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
PubMed
Dergi:
Panminerva Med
Yazar(lar) :
Kamal Dua , Jyotsana R Madan , Dinesh K Chellappan , Gaurav Gupta
Yıl :
2018
Dinesh K Chellappan
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
DOI : 10.23736/S0031-0808.18.03442-0
Sınıflandırma :
3
Targeting bacterial biofilms in pulmonary diseases in pediatric population.
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
PubMed
Dergi:
Minerva Pediatr.
Yazar(lar) :
Kamal Dua , Gaurav Gupta , Dinesh K Chellappan , Shakti Shukla , Philip M Hansbro
Yıl :
2018
Dinesh K Chellappan
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
DOI : 10.23736/S0026-4946.18.05256-8
Sınıflandırma :
4
Current therapies and targets for type 2 diabetes mellitus.
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
PubMed
Dergi:
Panminerva Med
Yazar(lar) :
Dinesh K Chellappan , Wei S Yap , Nurfatihah A Bt Ahmad Suhaimi , Gaurav Gupta , Kamal Dua
Yıl :
2018
Dinesh K Chellappan
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
The prevalence of type 2 diabetes mellitus (T2DM) has been increasing at an alarming rate. With an increased understanding of the pathophysiology and pathogenesis of T2DM, various new therapeutic options have been developed to target different key defects in T2DM. Incremental innovations of existing therapies either through unprecedented drug combinations, modified drug molecules, or improved delivery systems are capable to nullify some of the undesirable side effects of traditional therapies as well as to enhance effectiveness. The existing administration routes include inhalation, nasal, buccal, parenteral and oral. Newer drug targets such as protein kinase B (Akt/PKB), AMP-activated protein kinase (AMPK), sirtuin (SIRT), and others are novel approaches that act via different mechanisms and possibly treating T2DM of distinct variations and aetiologies. Other therapies such as endobarrier, gene therapy, and stem cell technology utilize advanced techniques to treat T2DM, and the potential of these therapies are still being explored. Gene therapy is plausible to fix the underlying pathology of T2DM instead of using traditional reactive treatments, especially with the debut of Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR associated protein9 (CRISPR-Cas9) gene editing tool. Molecular targets in T2DM are also being extensively studied as it could target the defects at the molecular level. Furthermore, antibody therapies and vaccinations are also being developed against T2DM; but the ongoing clinical trials are relatively lesser and the developmental progress is slower. Although, there are many therapies designed to cure T2DM, each of them has their own advantages and disadvantages. The preference for the treatment plan usually depends on the health status of the patient and the treatment goal. Therefore, an ideal treatment should take patient's compliance, efficacy, potency, bioavailability, and other pharmacological and non-pharmacological properties into account.
DOI : 10.23736/S0031-0808.18.03455-9
Sınıflandırma :
5
Peroxisome proliferator-activated receptor gamma: promising target in glioblastoma.
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
PubMed
Dergi:
Panminerva Med
Yazar(lar) :
Gaurav Gupta , Gautam Singhvi , Dinesh K Chellappan , Sanjay Sharma , Anurag Mishra , Rajiv Dahiya , Terezinha de Jesus Andreoli Pinto , Kamal Dua
Yıl :
2018
Dinesh K Chellappan
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
Glioblastoma, also known as glioblastoma multiforme, is the most common and worldwide-spread cancer that begins within the brain. Glioblastomas represent 15% of brain tumors. The most common length of survival following diagnosis is 12 to 14 months with less than 3% to 5% of people surviving longer than five years. Without treatment, survival is typically 3 months. Among all receptors, special attention has been focused on the role of peroxisome proliferator-activated receptors (PPARs) in glioblastoma. PPARs are ligand-activated intracellular transcription factors. The PPAR subfamily consists of three subtypes encoded by distinct genes named PPARα, PPARβ/δ, and PPARγ. PPARγ is the most extensively studied subtype of PPAR. There has been interesting preliminary evidence suggesting that diabetic patients receiving PPARγ agonists, a group of anti-diabetics, thiazolidinedione drugs, have an increased median survival for glioblastoma. In this paper, the recent progresses in understanding the potential mechanism of PPARγ in glioblastoma are summarized.
DOI : 10.23736/S0031-0808.18.03462-6
Sınıflandırma :
6
RAAS blockers in hypertension posing a higher risk toward the COVID ‐19
Dergi Makalesi

Dergi Makalesi
Kaynak :
Wiley Online Library
Dergi:
Dermatologic Therapy
Yazar(lar) :
Yogendra Singh , Gaurav Gupta , Saurabh Satija , Poonam Negi , Dinesh K. Chellappan , Kamal Dua
Konu :
Dermatology, General Medicine
Yıl :
2020
Dinesh K. Chellappan
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
DOI : 10.1111/dth.13501
ISSN: 1396-0296
Sayı: 4
Cilt: 33

7
Potentialities of aptasensors in cancer diagnosis
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
Materials Letters
Yayıncı:
Elsevier BV
Yazar(lar) :
Avinash Sharma , Kanika Dulta , Rupak Nagraik , Kamal Dua , Sachin K. Singh , Dinesh K. Chellappan , Deepak Kumar , Dong-Soo Shin
Yıl :
2022
Dinesh K. Chellappan
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Cancer is a potentially fatal disease that affects people worldwide. Cancer diagnosis at a later stage is a major challenge today, and will provide essential, faster and more accurate treatment using novel diagnostic techniques. Unfortunately, traditional methods of diagnosis have not been fully helpful and most cancers are diagnosed too late. Early-stage and sensitive diagnostics for various kinds of cancer can assist patients in gaining access to the best treatment options available to combat these diseases. Development of a quick, simple, portable, and low-cost method for detecting cancer diseases is critical. As a result, biosensors have become one of the most important study fields in recent years as a potentially beneficial tool for the identification and detection of a variety of cancer cells in the early stage. Aptasensors (aptamers-based biosensors) are one of several new detection approaches that have lately showed promise in terms of sensitivity, detection or identification, of all types of cancer cells. Aptasensors can detect small and very high-selectivity cancer markers, as well as optimized time and cost savings. In this report, we discussed the current issues of aptasensors in cancer diagnostics, as well its potential future prospects.
DOI : 10.1016/j.matlet.2021.131240
Anahtar Kelimeler : Cancer, Diagnosis, Biosensors, Aptasensors, Aptamers
ISSN: 0167-577X
Cilt: 308
Sayfa: 131240
8
Immunological axis of curcumin-loaded vesicular drug delivery systems.
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
PubMed
Dergi:
Future Med Chem
Yazar(lar) :
Dinesh K Chellappan , Zhao Yin Ng , Jin-Ying Wong , Alan Hsu , Peter Wark , Nicole Hansbro , Jack Taylor , Jithendra Panneerselvam , Thiagarajan Madheswaran , Gaurav Gupta , Mary Bebawy , Philip M Hansbro , Kamal Dua
Yıl :
2018
Dinesh K Chellappan
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
Several vesicular systems loaded with curcumin have found their way in the therapeutic applications of several diseases, primarily acting through their immunological pathways. Such systems use particles at a nanoscale range, bringing about their intended use through a range of complex mechanisms. Apart from delivering drug substances into target tissues, these vesicular systems also effectively overcome problems like insolubility and unequal drug distribution. Several mechanisms are explored lately by different workers, and interest over vesicular curcumin has been renewed in the past decade. This commentary discusses several immunological targets in which curcumin is employed in a vesicular form.
DOI : 10.4155/fmc-2017-0245
Anahtar Kelimeler : curcumin, drug delivery, immunological axis, liposomes, nanoparticles, vesicular systems
Sınıflandırma :
Biyotıp %100
Nörokimya %93
9
Emerging trends in nanomedicine for topical delivery in skin disorders: Current and translational approaches
Dergi Makalesi

Dergi Makalesi
Kaynak :
Wiley Online Library
Dergi:
Dermatologic Therapy
Yazar(lar) :
Parijat Pandey , Saurabh Satija , Ridhima Wadhwa , Meenu Mehta , Deepika Purohit , Gaurav Gupta , Parteek Prasher , Dinesh K. Chellappan , Rajendra Awasthi , Harish Dureja , Kamal Dua
Konu :
Dermatology, General Medicine
Yıl :
2020
Dinesh K. Chellappan
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
DOI : 10.1111/dth.13292
ISSN: 1396-0296
Sayı: 3
Cilt: 33

10
Molecular signaling of G‐protein‐coupled receptor in chronic heart failure and associated complications
Dergi Makalesi

Dergi Makalesi
Kaynak :
Wiley Online Library
Dergi:
Drug Development Research
Yazar(lar) :
Mohammad Altamish , Vijaya Paul Samuel , Rajiv Dahiya , Yogendra Singh , Pran Kishore Deb , Hamid A. Bakshi , Murtaza M. Tambuwala , Dinesh K. Chellappan , Trudi Collet , Kamal Dua , Gaurav Gupta
Konu :
Drug Discovery
Yıl :
2019
Dinesh K. Chellappan
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
The well‐known condition of heart failure is a clinical syndrome that results when the myocardium's ability to pump enough blood to meet the body's metabolic needs is impaired. Most of the cardiac activity is maintained by adrenoceptors, are categorized into two main α and β and three distinct subtypes of β receptor: β1‐, β2‐, and β3‐adrenoceptors. The β adrenoreceptor is the main regulatory macro proteins, predominantly available on heart and responsible for down regulatory cardiac signaling. Moreover, the pathological involvement of Angiotensin‐converting enzyme 1 (ACE1)/angiotensin II (Ang II)/angiotensin II type 1 (AT1) axis and beneficial ACE2/Ang (1‐7)/Mas receptor axis also shows protective role via Gi βγ, during heart failure these receptors get desensitized or internalized due to increase in the activity of G‐protein‐coupled receptor kinase 2 (GRK2) and GRK5, responsible for phosphorylation of G‐protein‐mediated down regulatory signaling. Here, we investigate the various clinical and preclinical data that exhibit the molecular mechanism of upset level of GRK change the cardiac activity during failing heart.
DOI : 10.1002/ddr.21627
ISSN: 0272-4391
Sayı: 1
Cilt: 81
Sayfa: 23-31
11
Interleukin-13: A pivotal target against influenza-induced exacerbation of chronic lung diseases
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
Life Sciences
Yayıncı:
Elsevier BV
Yazar(lar) :
Madhur D. Shastri , Venkata Sita Rama Raju Allam , Shakti D. Shukla , Niraj Kumar Jha , Keshav Raj Paudel , Gregory M. Peterson , Rahul P. Patel , Philip M. Hansbro , Dinesh K. Chellappan , Kamal Dua
Yıl :
2021
Dinesh K. Chellappan
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Non-communicable, chronic respiratory diseases (CRDs) affect millions of individuals worldwide. The course of these CRDs (asthma, chronic obstructive pulmonary disease, and cystic fibrosis) are often punctuated by microbial infections that may result in hospitalization and are associated with increased risk of morbidity and mortality, as well as reduced quality of life. Interleukin-13 (IL-13) is a key protein that regulates airway inflammation and mucus hypersecretion. There has been much interest in IL-13 from the last two decades. This cytokine is believed to play a decisive role in the exacerbation of inflammation during the course of viral infections, especially, in those with pre-existing CRDs. Here, we discuss the common viral infections in CRDs, as well as the potential role that IL-13 plays in the virus-induced disease pathogenesis of CRDs. We also discuss, in detail, the immune-modulation potential of IL-13 that could be translated to in-depth studies to develop IL-13-based therapeutic entities.
DOI : 10.1016/j.lfs.2021.119871
Anahtar Kelimeler : IL-13, Chronic respiratory diseases (CRDs), Asthma, COPD, Cystic fibrosis, COVID, IL-33, Eosinophils, Innate lymphoid cells (ILC2s)
ISSN: 0024-3205
Cilt: 283
Sayfa: 119871
12
Plants derived therapeutic strategies targeting chronic respiratory diseases: Chemical and immunological perspective
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
Chemico-Biological Interactions
Yayıncı:
Elsevier
Yazar(lar) :
Parteek Prasher , Mousmee Sharma , Meenu Mehta , Keshav R. Paudel , Saurabh Satija , Dinesh K. Chellappan , Harish Dureja , Gaurav Gupta , Murtaza M. Tambuwala , Poonam Negi , Peter R. Wich , Nicole G. Hansbro , Philip M. Hansbro , Kamal Dua
Yıl :
2020
Dinesh K. Chellappan
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
The apparent predicament of the representative chemotherapy for managing respiratory distress calls for an obligatory deliberation for identifying the pharmaceuticals that effectively counter the contemporary intricacies associated with target disease. Multiple, complex regulatory pathways manifest chronic pulmonary disorders, which require chemotherapeutics that produce composite inhibitory effect. The cost effective natural product based molecules hold a high fervor to meet the prospects posed by current respiratory-distress therapy by sparing the tedious drug design and development archetypes, present a robust standing for the possible replacement of the fading practice of poly-pharmacology, and ensure the subversion of a potential disease relapse. This study summarizes the experimental evidences on natural products moieties and their components that illustrates therapeutic efficacy on respiratory disorders.
DOI : 10.1016/j.cbi.2020.109125
Anahtar Kelimeler : COPD, Natural products, Respiratory disorders, Alkaloids, Flavonoids
ISSN: 0009-2797
Cilt: 325
Sayfa: 109125
Sınıflandırma :
13
Probing 3CL protease: Rationally designed chemical moieties for COVID ‐19
Dergi Makalesi

Dergi Makalesi
Kaynak :
Wiley Online Library
Dergi:
Drug Development Research
Yazar(lar) :
Mousmee Sharma , Parteek Prasher , Meenu Mehta , Flavia C. Zacconi , Yogendra Singh , Deepak N. Kapoor , Harish Dureja , Dinesh M. Pardhi , Murtaza M. Tambuwala , Gaurav Gupta , Dinesh K. Chellappan , Kamal Dua , Saurabh Satija
Konu :
Drug Discovery
Yıl :
2020
Dinesh K. Chellappan
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
DOI : 10.1002/ddr.21724
ISSN: 0272-4391
Sayı: 8
Cilt: 81
Sayfa: 911-918
14
Emerging concepts and directed therapeutics for the management of asthma: regulating the regulators
Dergi Makalesi

Dergi Makalesi
Kaynak :
Springer Link
Dergi:
Inflammopharmacology
Yazar(lar) :
Madhur D. Shastri , Wai Chin Chong , Kamal Dua , Gregory M. Peterson , Rahul P. Patel , Malik Q. Mahmood , Murtaza Tambuwala , Dinesh K. Chellappan , Nicole G. Hansbro , Shakti D. Shukla , Philip M. Hansbro
Konu :
Pharmacology (medical), Pharmacology, Immunology
Yıl :
2020
Dinesh K. Chellappan
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Asthma is a common, heterogeneous and serious disease, its prevalence has steadily risen in most parts of the world, and the condition is often inadequately controlled in many patients. Hence, there is a major need for new therapeutic approaches. Mild-to-moderate asthma is considered a T-helper cell type-2-mediated inflammatory disorder that develops due to abnormal immune responses to otherwise innocuous allergens. Prolonged exposure to allergens and persistent inflammation results in myofibroblast infiltration and airway remodelling with mucus hypersecretion, airway smooth muscle hypertrophy, and excess collagen deposition. The airways become hyper-responsive to provocation resulting in the characteristic wheezing and obstructed airflow experienced by patients. Extensive research has progressed the understanding of the underlying mechanisms and the development of new treatments for the management of asthma. Here, we review the basis of the disease, covering new areas such as the role of vascularisation and microRNAs, as well as associated potential therapeutic interventions utilising reports from animal and human studies. We also cover novel drug delivery strategies that are being developed to enhance therapeutic efficacy and patient compliance. Potential avenues to explore to improve the future of asthma management are highlighted.
DOI : 10.1007/s10787-020-00770-y
Anahtar Kelimeler : Asthma, Molecular mechanisms, Vascularisation, microRNA, Novel drug candidates, Targeted drug delivery
ISSN: 0925-4692 1568-5608
Sayı: 1
Cilt: 29
Sayfa: 15-33
15
Monotherapy of RAAS blockers and mobilization of aldosterone: A mechanistic perspective study in kidney disease
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
Chemico-Biological Interactions
Yayıncı:
Elsevier
Yazar(lar) :
Gaurav Gupta , Rajiv Dahiya , Yogendra Singh , Anurag Mishra , Aseem Verma , Sunil Kumar Gothwal , Alaa A.A. Aljabali , Harish Dureja , Parteek Prasher , Poonam Negi , Deepak N. Kapoor , Rohit Goyal , Murtaza M. Tambuwala , Dinesh K. Chellappan , Kamal Dua
Yıl :
2020
Dinesh K. Chellappan
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
In patients with acute kidney injury progressively converting into chronic kidney disease (CKD), proteinuria and high blood pressure predict progression to end-stage renal disease (ESRD). Although, Renin-angiotensin-aldosterone system (RAAS) regulates blood pressure and kidney disease through both direct and indirect mechanisms. RAAS blockers that act at the level of angiotensin or lower in the cascade can cause compensatory increases in the plasma renin and angiotensin II level. Here, in this review article, we are exploring the evidence-based on RAAS blockade action releases of aldosterone and hypothesizing the molecular mechanism for converting the acute kidney injury into chronic kidney disease to end-stage renal disease.
DOI : 10.1016/j.cbi.2020.108975
ISSN: 0009-2797
Cilt: 317
Sayfa: 108975
Sınıflandırma :
16
Dynamics of Prolyl Hydroxylases Levels During Disease Progression in Experimental Colitis
Dergi Makalesi

Dergi Makalesi
Kaynak :
Springer Link
Dergi:
Inflammation
Yazar(lar) :
Hamid A. Bakshi , Vijay Mishra , Saurabh Satija , Meenu Mehta , Faruk L. Hakkim , Prashant Kesharwani , Kamal Dua , Dinesh K. Chellappan , Nitin B. Charbe , Garima Shrivastava , S. Rajeshkumar , Alaa A. Aljabali , Bahaa Al-Trad , Kavita Pabreja , Murtaza M. Tambuwala
Konu :
Immunology, Immunology and Allergy
Yıl :
2019
Dinesh K. Chellappan
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Hypoxia inducible factor (HIF)-prolyl hydroxylase (PHD) inhibitors are shown to be protective in several models of inflammatory bowel disease (IBD). However, these non-selective inhibitors are known to inhibit all the three isoforms of PHD, i.e. PHD-1, PHD-2 and PHD-3. In the present report, we investigated the associated changes in levels of PHDs during the development and recovery of chemically induced colitis in mice. The results indicated that in the experimental model of murine colitis, levels of both, PHD-1 and PHD-2 were found to be increased with the progression of the disease; however, the level of PHD-3 remained the same in group of healthy controls and mice with colitis. Thus, the findings advocated that inhibitors, which inhibited all three isoforms of PHD could not be ideal therapeutics for IBD since PHD-3 is required for normal gut function. Hence, this necessitates the development of new compounds capable of selectively inhibiting PHD-1 and PHD-2 for effective treatment of IBD.
DOI : 10.1007/s10753-019-01065-3
Anahtar Kelimeler : prolyl hydroxylases, inflammatory bowel disease, colitis, disease activity index
ISSN: 0360-3997 1573-2576
Sayı: 6
Cilt: 42
Sayfa: 2032-2036
17
Current-status and applications of polysaccharides in drug delivery systems
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
Colloid and Interface Science Communications
Yayıncı:
Elsevier BV
Yazar(lar) :
Parteek Prasher , Mousmee Sharma , Meenu Mehta , Saurabh Satija , Alaa A. Aljabali , Murtaza M. Tambuwala , Krishnan Anand , Nitin Sharma , Harish Dureja , Niraj Kumar Jha , Gaurav Gupta , Monica Gulati , Sachin Kumar Singh , Dinesh K. Chellappan , Keshav R. Paudel , Philip M. Hansbro , Kamal Dua
Yıl :
2021
Dinesh K. Chellappan
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
The polysaccharide-based advanced drug delivery system owing to their biocompatibility, ability to encapsulate the drug molecules in their interspaces, and ability to achieve a controlled release of the cargo drug molecules result in improved drug pharmacokinetics. The drug-loaded polysaccharides possess ability to evade the multidrug-resistant microbial efflux pumps by aggregation effect, whereas the drug loaded polysaccharide-fabricated metal nanoparticles present an exceptional candidature for effectively transporting the drug molecules across the membrane barriers while enabling the theranostic applications at the same time. The biodegradability of polysaccharide based drug delivery systems ensure a sustained release of the encapsulated drug molecules, which minimizes the side effects caused by a burst release of the cargo therapeutics. These drug delivery systems proved highly beneficial for the NSAIDs that otherwise manifest ulcerogenic effect in the gastrointestinal tract. The large surface area of polysaccharides further provide a higher drug-loading capacity, which maintains the optimal concentration of the cargo drug at the target sites. The emerging applications of biodegradable polysaccharides in the designing of multicompartmental microspheres revolutionized tissue engineering, multi drug delivery, and cell culturing technologies. The present review deals with the current-status of polysaccharides as advanced drug delivery systems.
DOI : 10.1016/j.colcom.2021.100418
Anahtar Kelimeler : Polysaccharides, Drug delivery, Biocompatible
ISSN: 2215-0382
Cilt: 42
Sayfa: 100418
18
Anti-bacterial activity of inorganic nanomaterials and their antimicrobial peptide conjugates against resistant and non-resistant pathogens
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
International Journal of Pharmaceutics
Yayıncı:
Elsevier
Yazar(lar) :
Dinesh M. Pardhi , Didem Şen Karaman , Juri Timonen , Wei Wu , Qi Zhang , Saurabh Satija , Meenu Mehta , Nitin Charbe , Paul A. McCarron , Murtaza M. Tambuwala , Hamid A. Bakshi , Poonam Negi , Alaa A. Aljabali , Kamal Dua , Dinesh K. Chellappan , Ajit Behera , Kamla Pathak , Ritesh B. Watharkar , Jarkko Rautio , Jessica M. Rosenholm
Yıl :
2020
Dinesh K. Chellappan
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
This review details the antimicrobial applications of inorganic nanomaterials of mostly metallic form, and the augmentation of activity by surface conjugation of peptide ligands. The review is subdivided into three main sections, of which the first describes the antimicrobial activity of inorganic nanomaterials against gram-positive, gram-negative and multidrug-resistant bacterial strains. The second section highlights the range of antimicrobial peptides and the drug resistance strategies employed by bacterial species to counter lethality. The final part discusses the role of antimicrobial peptide-decorated inorganic nanomaterials in the fight against bacterial strains that show resistance. General strategies for the preparation of antimicrobial peptides and their conjugation to nanomaterials are discussed, emphasizing the use of elemental and metallic oxide nanomaterials. Importantly, the permeation of antimicrobial peptides through the bacterial membrane is shown to aid the delivery of nanomaterials into bacterial cells. By judicious use of targeting ligands, the nanomaterial becomes able to differentiate between bacterial and mammalian cells and, thus, reduce side effects. Moreover, peptide conjugation to the surface of a nanomaterial will alter surface chemistry in ways that lead to reduction in toxicity and improvements in biocompatibility.
DOI : 10.1016/j.ijpharm.2020.119531
Anahtar Kelimeler : NM Nanomaterial, Nanomaterial, NO Nitric oxide, Nitric oxide, Psi Mesoporous silicon, Mesoporous silicon, THC Thermal Hydrocarbonisation, Thermal Hydrocarbonisation, AMP Antimicrobial Peptides, Antimicrobial Peptides, SPION Superparamagnetic iron oxide, Superparamagnetic iron oxide, APTES 3-aminopropyltriethoxysilane, 3-aminopropyltriethoxysilane, Ln-ZnO Laurusnobilis-Zn oxide, Laurusnobilis-Zn oxide, CLSM Confocal laser scanning microscopy, Confocal laser scanning microscopy, FE-SEM Field emission scanning electron microscopy, Field emission scanning electron microscopy, CNT Carbon Nanotube, Carbon Nanotube, Ag Silver, Silver, Cu Copper, Copper, Au Gold, Gold, Zn Zinc, Zinc, Ga Gallium, Gallium, Al Aluminum, Aluminum, As Arsenic, Arsenic, Pt Platinum, Platinum, Hg Mercury, Mercury, TiO2 Titanium Dioxide, Titanium Dioxide, pG pristine graphene, pristine graphene, GO graphene oxide, graphene oxide, rGO reduced graphene oxide, reduced graphene oxide, G-QDs graphene quantum dots, graphene quantum dots, SWCNTs-Ag Ag coated SWCNTs-Ag, Ag coated SWCNTs-Ag, ZnO Zinc Oxide, Zinc Oxide, CuO Copper Oxide, Copper Oxide, LDH Layered double hydroxide, Layered double hydroxide, CNFs Carbon nanofibers, Carbon nanofibers, ACFs Activated carbon fiber, Activated carbon fiber, SEM Scanning Electron Microscopy, Scanning Electron Microscopy, TEM Transmission Electron Microscopy, Transmission Electron Microscopy, AA Amino Acid, Amino Acid, Ag-NM-L leaves Ag NM synthesised from Caltropisprocera, Ag NM synthesised from Caltropisprocera, CM-SH Cecropinmelittin with cysteine, Cecropinmelittin with cysteine, ICP-MS Inductively coupled plasma mass spectrometry, Inductively coupled plasma mass spectrometry, A3-APOHis C-terminally hexahistidine-tagged A3-APO, C-terminally hexahistidine-tagged A3-APO, i.v intravenous, intravenous, Au NM-Apt Au NM-DNA aptamer, Au NM-DNA aptamer, Au NM-AptHis Au NM conjugated with His-tag DNA aptamer, Au NM conjugated with His-tag DNA aptamer, PEP AMP (PEP) from lactoferrin, AMP (PEP) from lactoferrin, NQR NADH: ubiquinone oxidoreductase, NADH: ubiquinone oxidoreductase, TBARS Thiobarbituric acid-reactive substances, Thiobarbituric acid-reactive substances, ONMG o-nitrophenol β-du2013galactopyranosideside, o-nitrophenol β-du2013galactopyranosideside, Ag NM-SiNW Si nanowire composite with Ag NM, Si nanowire composite with Ag NM, Cu NM- SiNW Si nanowire composite with CuNM, Si nanowire composite with CuNM, Ag-MESs Ag encapsulated mesoporous silica nanocrystals, Ag encapsulated mesoporous silica nanocrystals, DNA Deoxyribonucleic acid, , Deoxyribonucleic acid, , RNA Ribonucleic acid, Ribonucleic acid, MSSA Methicillin-sensitive Staphylococcus aureus, Methicillin-sensitive Staphylococcus aureus, MRSA Methicillin-resistant Staphylococcus aureus, Methicillin-resistant Staphylococcus aureus, MRSE Methicillin-resistant Staphylococcus epidermidis, Methicillin-resistant Staphylococcus epidermidis, V2O5 Vanadium pentoxide V2O5, Vanadium pentoxide V2O5, OM Outer membrane, Outer membrane, PM Plasma membrane, Plasma membrane, PGN Peptidoglycan, Peptidoglycan, LTA Lipoteichoic acid, Lipoteichoic acid, MLT Maltose transporter, Maltose transporter, Nanomaterial, Antimicrobial, Conjugates, Antimicrobial peptides, Antibiotics
ISSN: 0378-5173
Cilt: 586
Sayfa: 119531
Sınıflandırma :
19
Overview of key molecular and pharmacological targets for diabetes and associated diseases
Dergi Makalesi

Dergi Makalesi
Kaynak :
Science Direct
Dergi:
Life Sciences
Yayıncı:
Elsevier BV
Yazar(lar) :
Seyed Hossein Shahcheraghi , Alaa A.A. Aljabali , Mazhar S. Al Zoubi , Vijay Mishra , Nitin B. Charbe , Yusuf A. Haggag , Garima Shrivastava , Abdulmajeed G. Almutary , Abdullah M. Alnuqaydan , Debmalya Barh , Kamal Dua , Dinesh K. Chellappan , Gaurav Gupta , Marzieh Lotfi , Ángel Serrano-Aroca , Bojlul Bahar , Yogendra Kumar Mishra , Kazuo Takayama , Pritam Kumar Panda , Hamid A. Bakshi , Murtaza M. Tambuwala
Yıl :
2021
Dinesh K. Chellappan
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Diabetes epidemiological quantities are demonstrating one of the most important communities' health worries. The essential diabetic difficulties are including cardiomyopathy, nephropathy, inflammation, and retinopathy. Despite developments in glucose decreasing treatments and drugs, these diabetic complications are still ineffectively reversed or prohibited. Several signaling and molecular pathways are vital targets in the new therapies of diabetes. This review assesses the newest researches about the key molecules and signaling pathways as targets of molecular pharmacology in diabetes and diseases related to it for better treatment based on molecular sciences. The disease is not cured by current pharmacological strategies for type 2 diabetes. While several drug combinations are accessible that can efficiently modulate glycemia and mitigate long-term complications, these agents do not reverse pathogenesis, and in practice, they are not established to modify the patient's specific molecular profiling. Therapeutic companies have benefited from human genetics. Genome exploration, which is agnostic to the information that exists, has revealed tens of loci that impact glycemic modulation. The physiological report has begun to examine subtypes of diseases, illustrate heterogeneity and propose biochemical therapeutic pathways.
DOI : 10.1016/j.lfs.2021.119632
Anahtar Kelimeler : EC Endothelial cell, Endothelial cell, AGE Advanced Glycation End Products, Advanced Glycation End Products, ECD Endothelial Cell Dysfunction, Endothelial Cell Dysfunction, DCM Diabetic cardiomyopathy, Diabetic cardiomyopathy, PPARα Peroxisome proliferator-activated receptor α, Peroxisome proliferator-activated receptor α, GLP-1 Glucagon like peptide-1, Glucagon like peptide-1, YAP Yes-associated protein, Yes-associated protein, PRR Pro renin receptor, Pro renin receptor, Ad-PRR Adenoviruses-carried-PRR-gene, Adenoviruses-carried-PRR-gene, LXA4 Lipoxin A4, Lipoxin A4, O-GlcNAc O-linked N-acetylglucosamine, O-linked N-acetylglucosamine, ROS Reactive oxygen species, Reactive oxygen species, PKCβ Protein kinase C β, Protein kinase C β, PKB or Akt Protein kinase B, Protein kinase B, PI3K Phosphoinositide 3-kinase, Phosphoinositide 3-kinase, PKR Protein kinase RNA, Protein kinase RNA, IRE1 Inositol-requiring enzyme-1, Inositol-requiring enzyme-1, BMP9 Bone morphogenetic protein-9, Bone morphogenetic protein-9, HMGB1 High-mobility group box 1 protein, High-mobility group box 1 protein, TLR4 Toll-like receptor 4, Toll-like receptor 4, TGF-β Transforming growth factor beta, Transforming growth factor beta, VEGF Vascular endothelial growth factor, Vascular endothelial growth factor, MAPK Mitogenactivated protein kinase, Mitogenactivated protein kinase, HIF-1 Hypoxia inducible factor-1, Hypoxia inducible factor-1, DR Diabetic retinopathy, Diabetic retinopathy, miRNAs microRNAs, microRNAs, T2D Type 2 diabetes, Type 2 diabetes, DN Diabetic nephropathy, Diabetic nephropathy, NF-κB Nuclear factor-κB, Nuclear factor-κB, GPR120 G protein-coupled receptor 120, G protein-coupled receptor 120, GPER G protein-coupled estrogen receptor, G protein-coupled estrogen receptor, TNF-α Tumor necrosis factor- alpha, Tumor necrosis factor- alpha, Nrf-2 Nuclear factor erythroid 2-related factor 2, Nuclear factor erythroid 2-related factor 2, JNK c-Jun amino terminal kinase, c-Jun amino terminal kinase, BHB β-hydroxybutyrate, β-hydroxybutyrate, HSPs Heat shock proteins, Heat shock proteins, GSK-3β Glycogen synthesis kinase-3β, Glycogen synthesis kinase-3β, mTOR mammalian target of rapamycin, mammalian target of rapamycin, ICAM-1 Intercellular adhesion molecule 1, Intercellular adhesion molecule 1, Diabetes, Diabetic complications, Signaling pathways, Molecular pharmacology, Targets
ISSN: 0024-3205
Cilt: 278
Sayfa: 119632
20
Cellular signalling pathways mediating the pathogenesis of chronic inflammatory respiratory diseases: an update
Dergi Makalesi

Dergi Makalesi
Kaynak :
Springer Link
Dergi:
Inflammopharmacology
Yazar(lar) :
Meenu Mehta , Daljeet S. Dhanjal , Keshav R. Paudel , Bhupender Singh , Gaurav Gupta , S. Rajeshkumar , Lakshmi Thangavelu , Murtaza M. Tambuwala , Hamid A. Bakshi , Dinesh K. Chellappan , Parijat Pandey , Harish Dureja , Nitin B. Charbe , Sachin K. Singh , Shakti D. Shukla , Srinivas Nammi , Alaa A. Aljabali , Peter R. Wich , Philip M. Hansbro , Saurabh Satija , Kamal Dua
Konu :
Pharmacology (medical), Pharmacology, Immunology
Yıl :
2020
Dinesh K. Chellappan
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Respiratory disorders, especially non-communicable, chronic inflammatory diseases, are amongst the leading causes of mortality and morbidity worldwide. Respiratory diseases involve multiple pulmonary components, including airways and lungs that lead to their abnormal physiological functioning. Several signaling pathways have been reported to play an important role in the pathophysiology of respiratory diseases. These pathways, in addition, become the compounding factors contributing to the clinical outcomes in respiratory diseases. A range of signaling components such as Notch, Hedgehog, Wingless/Wnt, bone morphogenetic proteins, epidermal growth factor and fibroblast growth factor is primarily employed by these pathways in the eventual cascade of events. The different aberrations in such cell-signaling processes trigger the onset of respiratory diseases making the conventional therapeutic modalities ineffective. These challenges have prompted us to explore novel and effective approaches for the prevention and/or treatment of respiratory diseases. In this review, we have attempted to deliberate on the current literature describing the role of major cell signaling pathways in the pathogenesis of pulmonary diseases and discuss promising advances in the field of therapeutics that could lead to novel clinical therapies capable of preventing or reversing pulmonary vascular pathology in such patients.
DOI : 10.1007/s10787-020-00698-3
Anahtar Kelimeler : Cell signaling, Respiratory diseases, Wnt pathway, Inflammatory
ISSN: 0925-4692 1568-5608
Sayı: 4
Cilt: 28
Sayfa: 795-817
21
Targeting neutrophils using novel drug delivery systems in chronic respiratory diseases
Dergi Makalesi

Dergi Makalesi
Kaynak :
Wiley Online Library
Dergi:
Drug Development Research
Yazar(lar) :
Dinesh K. Chellappan , Lim W. Yee , Kong Y. Xuan , Kishen Kunalan , Lim C. Rou , Leong S. Jean , Lee Y. Ying , Lee X. Wie , Jestin Chellian , Meenu Mehta , Saurabh Satija , Sachin K. Singh , Monica Gulati , Harish Dureja , Mateus Webba Da Silva , Murtaza M. Tambuwala , Gaurav Gupta , Keshav R. Paudel , Ridhima Wadhwa , Philip M. Hansbro , Kamal Dua
Konu :
Drug Discovery
Yıl :
2020
Dinesh K. Chellappan
Yayıncı Web Sitesi
Tam Metin
Kaydet Alıntıla
Neutrophils are essential effector cells of immune system for clearing the extracellular pathogens during inflammation and immune reactions. Neutrophils play a major role in chronic respiratory diseases. In respiratory diseases such as asthma, chronic obstructive pulmonary disease, cystic fibrosis, lung cancer and others, there occurs extreme infiltration and activation of neutrophils followed by a cascade of events like oxidative stress and dysregulated cellular proteins that eventually result in apoptosis and tissue damage. Dysregulation of neutrophil effector functions including delayed neutropil apoptosis, increased neutrophil extracellular traps in the pathogenesis of asthma, and chronic obstructive pulmonary disease enable neutrophils as a potential therapeutic target. Accounting to their role in pathogenesis, neutrophils present as an excellent therapeutic target for the treatment of chronic respiratory diseases. This review highlights the current status and the emerging trends in novel drug delivery systems such as nanoparticles, liposomes, microspheres, and other newer nanosystems that can target neutrophils and their molecular pathways, in the airways against infections, inflammation, and cancer. These drug delivery systems are promising in providing sustained drug delivery, reduced therapeutic dose, improved patient compliance, and reduced drug toxicity. In addition, the review also discusses emerging strategies and the future perspectives in neutrophil‐based therapy.
DOI : 10.1002/ddr.21648
ISSN: 0272-4391
Sayı: 4
Cilt: 81
Sayfa: 419-436
22
Dietary Crocin is Protective in Pancreatic Cancer while Reducing Radiation-Induced Hepatic Oxidative Damage
Dergi Makalesi

Dergi Makalesi
Open Access
Kaynak :
Directory of Open Access Journals (DOAJ)
Dergi:
Nutrients
Yazar(lar) :
Hamid A. Bakshi , Mazhar S Al Zoubi , Hakkim L. Faruck , Alaa A A Aljabali , Firas A. Rabi , Amin A. Hafiz , Khalid M Al-Batanyeh , Bahaa Al-Trad , Prawej Ansari , Mohamed M. Nasef , Nitin B. Charbe , Saurabh Satija , Meenu Mehta , Vijay Mishra , Gaurav Gupta , Salem Abobaker , Poonam Negi , Ibrahim M. Azzouz , Ashref Ali K Dardouri , Harish Dureja , Parteek Prasher , Dinesh K. Chellappan , Kamal Dua , Mateus Webba Da Silva , Mohamed El Tanani , Paul A. McCarron , Murtaza M. Tambuwala
Yıl :
2020
Dinesh K. Chellappan
Yayıncı Web Sitesi
 Piri Tam Metin Bulucu
Kaydet Alıntıla
Pancreatic cancer is one of the fatal causes of global cancer-related deaths. Although surgery and chemotherapy are standard treatment options, post-treatment outcomes often end in a poor prognosis. In the present study, we investigated anti-pancreatic cancer and amelioration of radiation-induced oxidative damage by crocin. Crocin is a carotenoid isolated from the dietary herb saffron, a prospect for novel leads as an anti-cancer agent. Crocin significantly reduced cell viability of BXPC3 and Capan-2 by triggering caspase signaling via the downregulation of Bcl-2. It modulated the expression of cell cycle signaling proteins P53, P21, P27, CDK2, c-MYC, Cyt-c and P38. Concomitantly, crocin treatment-induced apoptosis by inducing the release of cytochrome c from mitochondria to cytosol. Microarray analysis of the expression signature of genes induced by crocin showed a substantial number of genes involved in cell signaling pathways and checkpoints (723) are significantly affected by crocin. In mice bearing pancreatic tumors, crocin significantly reduced tumor burden without a change in body weight. Additionally, it showed significant protection against radiation-induced hepatic oxidative damage, reduced the levels of hepatic toxicity and preserved liver morphology. These findings indicate that crocin has a potential role in the treatment, prevention and management of pancreatic cancer.
DOI : 10.3390/nu12061901
Anahtar Kelimeler : pancreatic cancer, crocin, apoptosis, cell cycle, radiation, hepatic injury
ISSN: 2072-6643
Cilt: 12
Sayı: 1901
Sayfa: 1901
Sınıflandırma :
Biyotıp %100
Biyotıp %100

Yayın Yılı

Sınırla

Doküman Türü
Tümü

Veri Tabanı
Tümü

Dergi İsmi
Tümü

Disiplin
Tümü

Disipline Göre İlgililik

Alt Disiplin
Tümü

Konu
Tümü

Yayıncı
Tümü

Lisan
Tümü

X
Filtreler